Selection and Use of Melatonin Supporting Bacteria to Reduce Infantile Colic
AssigneeBiogaia AB
InventorsStefan Roos, Bo Möllstam
Life of this patent
Estimating the term…
Abstract
The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of melatonin, for use in the production of melatonin in a subject. Preferred strains for such uses are capable of producing or inducing the production of adenosine. Therapeutic uses of such strains include the treatment or prevention of diseases associated with melatonin deficiency, for example infantile colic. Novel strains are also provided.
Claims23
-34. (canceled)
A method of treating infantile colic in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a Lactobacillus reuteri strain that is capable of producing or inducing the production of melatonin or adenosine;
- wherein said strain has 5′-nucleotidase activity, and/or is capable of producing or inducing the production of adenosine, and/or is capable of producing or inducing the production of melatonin, at a level which is increased as compared to Lactobacillus reuteri DSM 17938.
A method of treating irritable bowel syndrome (IBS), sleep disorders, or neurodegenerative diseases in a subject, comprising administering to the subject a therapeutically effective amount of a Lactobacillus reuteri strain that is capable of producing or inducing the production of melatonin or adenosine;
- wherein said strain has 5′-nucleotidase activity, and/or is capable of producing or inducing the production of adenosine, and/or is capable of producing or inducing the production of melatonin, at a level which is increased as compared to Lactobacillus reuteri DSM 17938.
A bacterial strain, wherein said bacterial strain is Lactobacillus reuteri DSM 32846, DSM 32847, DSM 32849 and/or DSM 33198.
A method of isolating a lactic acid bacterial strain capable of producing adenosine, wherein said strain is Lactobacillus reuteri and wherein said method comprises:
- a) screening the Lactobacillus reuteri strain for the presence of a gene encoding a 5′-nucleotidase and/or screening the Lactobacillus reuteri strain or its supernatant, for the presence of an active 5′-nucleotidase enzyme;
- b) detecting the presence of a gene encoding a 5′-nucleotidase and/or an active 5′-nucleotidase enzyme;
- c) isolating the Lactobacillus reuteri strain, wherein the strain is capable of producing adenosine at a level which is increased as compared to Lactobacillus reuteri DSM 17938;
- and optionally d) culturing or propagating the Lactobacillus reuteri strain.
A Lactobacillus reuteri strain that is capable of producing or inducing the production of melatonin or adenosine;
- wherein said strain has 5′-nucleotidase activity, and/or is capable of producing or inducing the production of adenosine, and/or is capable of producing or inducing the production of melatonin, at a level which is increased as compared to Lactobacillus reuteri DSM 17938.
Dependencies are inferred from the claim text.